34 results about "Viral therapy" patented technology

Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and / or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.

Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (TME) and methods of modifying a tumor microenvironment (TME). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces T-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred NK or T cells and / or induces production of an interleukin, an interferon, a PD-1 checkpoint binding protein, HMGB1, MyD88, a cytokine or a chemokine. Methods of modulating the suppression of the immune response in a tumor microenvironment, minimizing the proliferation of tumor and suppressive cells, and increasing the efficiency of an anti-cancer therapy, anti-infection therapy, antibacterial therapy, anti-viral therapy, or anti-tumoral therapy are also provided.

The present invention relates to compounds according to the general formula:wherein B isorand the remaining variables are defined in the specification, and compositions comprising the compounds. The compounds are useful as anti-viral agents in viral therapy.

The invention discloses a novel oncolytic virus based on vaccinia virus Tiantan strain. The thymidine kinase (TK) region of the virus contains a coding sequence of AIF-GM-CSF as shown in SEQ ID NO.1.The oncolytic vaccinia virus which can efficiently expressing a human AIF-GM-CSF gene is prepared by effectively combining the tumor suppression effect of gene therapy and the oncolytic effect of viral therapy. While the oncolytic virus of the vaccinia virus Tiantan strain achieves the oncolytic effect to pyrolyze tumor cells, human AIF is massively expressed to cause apoptosis of a great number of infected tumor cells; and a great number of human GM-CSF can be expressed, and NK cells or DC cells can be recruited into the inside of a tumor to kill the tumor or effectively represent a tumor antigen, so that proliferation and differentiation of cytotoxicity t cells can be improved, and multiple anti-tumor effects can be achieved. Compared with simple gene therapy or virus therapy, the malignant tumor killing performance of the novel oncolytic virus is reinforced.

The invention discloses a recombinant oncolytic vaccinia virus and a preparation method and application thereof. The thymidine kinase (TK) region of the virus comprises a coding sequence of a PD1 full-length antibody shown in the formula of SEQ ID NO.1. Through effective combination of the anti-tumor effect of gene therapy and the oncolytic effect of virus treatment, the oncolytic vaccinia virus for efficiently expressing the PD1 full-length antibody gene is prepared. When the oncolytic vaccinia virus produces the oncolytic effect of splitting tumor cells, the PD1 full-length antibody is efficiently expressed, the activity of PD1 on the surfaces of T cells is inhibited, the T cell immune response is activated and the dual antitumor effects are produced. Compared with the single gene therapy or viral therapy, the method using the recombinant oncolytic vaccinia virus improves the effects of killing malignant B cell lymphoma. Through virus replication-related gene deletion, the TK regionof the vaccinia virus genome is deleted so that specific replication of the viruses in the abnormally proliferating tumor cells is ensured and the viruses can not replicate in normal cells, so that the safety of the oncolytic vaccinia virus vector is greatly improved.

A purpose of the present invention is to develop an immuno-viral therapy vector that has an optimal therapeutic effect while ensuring a high degree of safety, on the basis of the novel concept of finding the optimal expression level of a therapeutic gene to bring about the maximum therapeutic effect with no side effects. The present invention provides an oncolytic virus or similar that is characterized by having an immunogenic gene that is functionally linked downstream of an E2F promoter or a promoter demonstrating the same activity as an E2F promoter, wherein a promoter of nucleic acids coding for at least one factor that is essential for virus replication or assembly is substituted with a promoter of a factor for which expression is organ-specifically enhanced, or a promoter of a factorfor which expression is cancer cell-specifically enhanced.

Embodiments enables a wearable phototherapy apparatus that produces beneficial effects to a human body such as anti-viral effects, activation of stem cells, improvement in strength, improvement in stamina, pain relief via a non-transdermal container. May include an optional transdermal container that releases or increases copper peptide GHK-Cu in a subject's body. The non-transdermal apparatus reflects or emits specific wavelengths of light to elevate levels of the copper peptide GHK-Cu in the body. The non-transdermal apparatus includes one or more materials that prevent the Left-Handed molecule from direct contact with the body while the enclosure is coupled to the body and prevents the Left-Handed molecules from entering the body. Embodiments may include or be used with any bioavailable form of copper, e.g., such as copper glycinate as an anti-viral therapy and may include an anti-inflammatory or both.

The present invention relates to novel compounds according to the general formulas I, II, III, IV or V:wherein B is nucleoside base according to the structure:and the remaining variables as defined in the specification, and pharmaceutical compositions comprising the compounds. The compounds are useful interalia as anti-viral agents in viral therapy.

The invention provides application of a recombinant oncolytic poxvirus in preparation of a pharmaceutical composition for treatment of lymphoma. An exogenous gene encoding scFvCD47 is inserted on an oncolytic poxvirus so as to obtain the recombinant oncolytic poxvirus (OVVscFvCD47), and the obtained recombinant oncolytic poxvirus is applied to the pharmaceutical composition for treatment of lymphoma. Gene therapy of malignant tumors is combined with viral therapy effectively, the oncolytic poxvirus capable of efficiently expressing scFvCD47 is prepared, and the ability of tumor killing is enhanced when the therapy is compared with pure gene therapy or viral therapy. A tumor-targeted therapy strategy is adopted, tumor cells can be targeted effectively, and specific proliferation in the tumor cells can be achieved, so that the safety of an oncolytic poxvirus vector is improved greatly. A virus replication mode for related gene deletion is adopted so as to ensure specific replication of the virus in tumor, and the safety of the oncolytic poxvirus vector is enhanced greatly. A good effect of lymphoma resistance is achieved through construction of the recombinant oncolytic poxvirus carrying the human scFvCD47 encoded sequence.

The present invention relates to a parvovirus for the treatment of mesenchymal tumors, preferably malignant bone tumors such as localized and metastasized bone tumors, in particular osteosarcoma and Ewing's sarcoma. A preferred parvovirus includes a replication competent parvovirus H-1PV.

A composition for expressing a polypeptide within a target organ, the composition comprising a delivery particle, and at least a first mRNA sequence complexed with, encapsulated by, or otherwise associated with the delivery particle. The mRNA sequence comprises a coding sequence which codes for the polypeptide, at least a first untranslated region (UTR) sequence, and at least one micro-RNA (miRNA)binding site sequence, wherein the miRNA binding site sequence is located within, immediately 5' to, or immediately 3' to, the first UTR sequence. The miRNA binding site sequence is selected so as toprovide for differential expression of the coding sequence between first and second cell types comprised within the target organ. The composition may be used in combination with or to supplement other therapeutic approaches, including chemotherapy, oncolytic viral therapy, and cellular therapies. Methods for making and using the composition are provided, particularly in treatment of disease, suchas cancer of the liver, brain, lung, breast and pancreas.

The invention relates to the technical field of biomedicine engineering, and provides an application of an STRIP (striatin interacting protein) inhibitor to preparation of an anti-tumor drug, a striatin interacting protein inhibitor recombinant vector, an application of the recombinant vector to preparation of the anti-tumor drug and an anti-tumor drug composition taking the striatin interacting protein inhibitor or the striatin interacting protein inhibitor recombinant vector as active components. The inhibitor for inhibiting a STRIP can be used for preparing the anti-tumor virus drug, particularly, the inhibitor and a vaccinia virus are recombined into the recombinant vector, the advantages of the STRIP inhibitor and the vaccinia virus can be combined, a new target spot is provided for viral therapy of tumors, and the STRIP inhibitor has a wide clinical application prospect.

Provided herein are methods for treating or ameliorating a solid tumor in a subject comprising administering oncolytic viruses and immunosuppressive agents at or near the site of the tumor.

This invention relates to methods of separating virally infected viable cells from dead cells using antibodies specific for intracellular proteins and a covalent nucleic acid binding agent. The method can be readily adapted for assessing viral infection and / or replication in viable cells, identifying anti-viral agent, and monitoring anti-viral therapy

This invention is directed to the treatment of cancers, e.g., inflammatory breast cancer, with NK (natural killer) cells wherein the cells are modified ex vivo such that their ability to overcome the chemorepellant effect of a tumor is enhanced. The cells may be genetically modified ex vivo and / or modified by contacting the cells ex vivo with an anti-chemorepellant agent. This invention also provides ex vivo modified NK cells, which are modified such that they express no or substantially no CXCR4 on their cell surface, or express CXCR7, or express a chimeric antigen receptor, or combinations thereof. The invention also relates to methods for treating a patient having a tumor, e.g., inflammatory breast cancer, by administering the modified NK cells, with or without treatment with other conventional anticancer treatments, e.g. , chemotherapy, radiotherapy, viral therapies, hormonal therapies, as well as other immunotherapies and anti-chemorepellant therapies.

The present invention relates to the field of viral therapy. More specifically, the present invention relates to the use of elderberry extract in the preparation of a pharmaceutical formulation for the treatment of an influenza viral infection. It also relates to a novel method of treatment of the avian flu virus, through the administration of elderberry extract.

The invention includes compositions that regulated PI3K p110 delta and are useful as an anti-viral therapy. The invention includes a method of inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-viral therapeutic approach for treating a viral infection, for example influenza. The invention includes a method of modulating PI3K p110 delta in a cell infected with a virus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.

The invention provides an application of a recombinant oncolytic virus in the preparation of drugs for treating digestive tract cancer, belongs to genetic engineering and oncology, and relates an application of a human IL-33-carrying recombinant oncolytic vaccinia virus in treating cancer. Through the effective combination of gene therapy for malignant tumors and viral therapy, an oncolytic vaccinia virus capable of efficiently expressing IL-33 can be prepared; and compared with simple gene therapy or viral therapy, killing abilities on tumors can be enhanced; through the adopting of a tumor targeted therapy strategy, tumor cells can be effectively targeted, and specific proliferation can be achieved, so that the safety of an oncolytic vaccinia virus vector can be greatly enhanced; throughthe adopting of the mode of virus replication related gene deletion, the intratumoral specific replication of the virus can be ensured, and the safety of the oncolytic vaccinia virus vector can be greatly enhanced; and through the construction of the human IL-33 carried recombinant oncolytic vaccinia virus, good anti-gastric, colon and pancreatic cancer effects can be achieved.

The invention provides a bispecific T cell adapter, a recombinant oncolytic virus thereof and application of the bispecific T cell adapter and the recombinant oncolytic virus. The invention provides an alphaCD47 (alpha CD47) and alphaCD3 (alpha CD3) bispecific T cell adapter. The invention also provides an isolated nucleic acid molecule which encodes the bispecific T cell adapter. The invention also provides an expression framework of the bispecific T cell adapter BiTE. The invention also provides a recombinant oncolytic virus, and the oncolytic virus is operably inserted into or comprises the expression framework of the bispecific T cell adapter BiTE. According to the present invention, the bispecific T cell adapter is combined with the oncolytic virus, and the oncolytic virus significantly enhances the ability to inhibit malignant tumors compared to a pure gene therapy or viral therapy.

The invention discloses a construction method and application of an hACE2 humanized transgenic pig. A CRISPR-Cas9 gene editing technology is adopted, hACE2cDNA is used for replacing an ACE2 gene of a pig, and the problem that a pig model cannot well reproduce human disease characteristics due to the fact that pig endogenous ACE2 is also expressed while humanized ACE2 is expressed is solved. The hACE2 humanized pig model constructed by the invention is an ideal large animal pig model capable of simulating clinical symptoms and treatment response of human COVID-19, can be used for research on SARS-CoV-2 infection and pathogenesis, and is particularly suitable for research on multi-organ diseases, severe diseases, chronic diseases and sequelae caused by SARS-CoV-2 infection, the model can be used for development and testing of diagnostic technology, antiviral therapy and vaccines and evaluation of curative effect and safety of candidate drugs, and is beneficial to solving the problem of lack of an effective new coronal pneumonia animal model at present.

The invention relates to methods for generating cell-type specific expression cassettes and reporter vectors, as well as nucleic acid constructs that can be generated by such methods. The cell-type specific expression cassettes and reporter vectors are characterized synthetic cis-regulatory DNA, also termed synthetic locus regions (sLCRs). sLCRs allow for a cell-type specific expression of reporter or effector genes. The invention further relates to various uses of the reporter vectors, including the determination of a property of a cell, preferably a cell type, state or fate transition, in gene and viral therapy, drug discovery or validation.

Provided herein are methods of treating cancer in a subject. The methods include administering to the subject one or more doses of an oncolytic virus (e.g., in an initial round of treatment); selecting a subject with a T-cell population exhibiting high peripheral clonality; and administering to the subject with a T-cell population exhibiting high peripheral clonality a one or more subsequent doses of the oncolytic virus (e.g., in a second round of treatment).

The invention discloses a novel oncolytic virus and its preparation method and application. The oncolytic virus genome contains gene coding sequences of anti-human CTLA4 antibody and human IL-21, and can express anti-human CTLA4 antibody and human IL-21 21. Combining the tumor-suppressing effect of immunotherapy with the oncolytic effect of viral therapy, an oncolytic virus capable of highly expressing the αCTLA4-Fc(ALIE)-IL21 gene was prepared, and the oncolytic virus exerted an oncolytic effect to lyse the tumor At the same time, it can kill regulatory T cells (Regulatory T Cells, Treg) in the tumor microenvironment by expressing a large amount of αCTLA4‑Fc (ALIE), or block its inhibitory effect, thereby up-regulating the immune response of the tumor microenvironment and improving the anti-tumor effect At the same time, the oncolytic virus expresses a large amount of IL21, further activates the killing function of T cells and NK cells in the tumor microenvironment, and exerts multiple anti-tumor effects. Compared with simple gene therapy or virus therapy, it has enhanced its ability to kill malignant tumors.

The invention relates to methods for generating cell-type specific expression cassettes and reporter vectors, as well as nucleic acid constructs that can be generated by such methods. The cell-type specific expression cassettes and reporter vectors are characterized synthetic cis-regulatory DNA, also termed synthetic locus regions (sLCRs). sLCRs allow for a cell-type specific expression of reporter or effector genes. The invention further relates to various uses of the reporter vectors, including the determination of a property of a cell, preferably a cell type, state or fate transition, in gene and viral therapy, drug discovery or validation.

Embodiments enables a wearable phototherapy apparatus that produces beneficial effects to a human body such as anti-viral effects, activation of stem cells, improvement in strength, improvement in stamina, pain relief via a non-transdermal container. May include an optional transdermal container that releases or increases copper peptide GHK-Cu in a subject's body. The non-transdermal apparatus reflects or emits specific wavelengths of light to elevate levels of the copper peptide GHK-Cu in the body. The non-transdermal apparatus includes one or more materials that prevent the Left-Handed molecule from direct contact with the body while the enclosure is coupled to the body and prevents the Left-Handed molecules from entering the body. Embodiments may include or be used with any bioavailable form of copper, e.g., such as copper glycinate as an anti-viral therapy and may include an anti-inflammatory or both.

A composition for expressing a polypeptide within a target organ, the composition comprising a delivery particle, and at least a first mRNA sequence complexed with, encapsulated by, or otherwise associated with the delivery particle. The mRNA sequence comprises a coding sequence which codes for the polypeptide, at least a first untranslated region (UTR) sequence, and at least one micro-RNA (miRNA) binding site sequence, wherein the miRNA binding site sequence is located within, immediately 5′ to, or immediately 3′ to, the first UTR sequence. The miRNA binding site sequence is selected so as to provide for differential expression of the coding sequence between first and second cell types comprised within the target organ. The composition may be used in combination with or to supplement other therapeutic approaches, including chemotherapy, oncolytic viral therapy, and cellular therapies. Methods for making and using the composition are provided, particularly in treatment of disease, such as cancer of the liver, brain, lung, breast and pancreas.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells thatare matched to subjects for such treatment.

There is provided a protein-RNA complex where here the protein is selected from one of Cpf1 and CAS13 and where the protein is Cpf1 and the RNA is an RNA guide strand which comprises a sequence that is one of SEQ ID NO 1 to 40 less the 5′ TTTN motif of said SEQ ID NO 1-40, or the protein is CAS13 and the polynucleotide is an RNA guide strand that comprises a sequence that is complimentary to one of SEQ ID NO 41 to 80.

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS 1 protein, wherein said vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine.